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Summary The expression of the regulatory (RI and RII) and catalytic (C) subunits of cAMP-dependent
protein kinase was found to depend on the growth-state in oestrogen-dependent DMBA-induced mammary
adenocarcinomas as well as in uteri of the rat. Castration-induced atrophy of the oestrogen-dependent tissues
was accompanied by a decrease of the concentration of regulatory subunits (RI and RII) relative to both the
catalytic subunit (C) and total protein, decreasing the R/protein and R/C ratios. A hyperplastic burst caused
by high-dose oestrogen-replacement treatment was associated with an increased level of RI and little change in
RII and C levels. Only minor differences were noted for the expression of mRNA for the a and P subtypes of
RI, RII and C between rat uteri from castrated and oestrogen-treated animals, or between mammary tumours
from normal and castrated animals. Expression of RIP-mRNA was detected only in the uterus. Our findings
provide an experimental correlate for the reported value of the parameter R/protein in human mammary
cancer biopsies to predict prognosis and outcome of therapy. Due to the sensitivity of the R/protein ratio
towards changes in extracellular protein content, we recommend the biologically more meaningful R/C ratio in
further clinical evaluations of mammary tumour biopsies.
The intracellular signal substance cAMP and its major
eukaryotic effector system, the cAMP-dependent protein
kinase (cAK), has a key role in regulating cell functions
ranging from intermediary metabolism to cell shape and
DNA replication. cAK is composed of a regulatory (R)
subunit dimer and two catalytic (C) subunits. Except for a
special form (Cy) of the catalytic subunit with mRNA expres-
sion in human testis (Beebe et al., 1990), only two forms (a,p)
are known of each type of regulatory (Rla, RIP; RIIa, RIIP)
and catalytic (Ca, CP) subunit (see Beebe & Corbin, 1986;
Edelman et al., 1987, for general reviews of cAMP-kinase).
Recent evidence indicates that cells made to overexpress or
underexpress specific subunits have altered growth charac-
teristics, and that cAMP action on cell growth, cell
differentiation and cell viability may depend on specific types
or forms of the cAMP kinase (see Cho-Chung, 1990 for a
review). Altered level of Rla-expression has recently been
shown to be necessary for tissue-specific gene regulation in
liver (Boshart et al., 1991; Jones et al., 1991). Differential
expression of cAK subunits can be on three levels:
1. Disproportionate accumulation of regulatory relative to
catalytic subunits of cAK, changing the R/C ratio.
2. Altered ratio between the two isozymes of cAK (type I
and type II).
3. Altered expression of the subforms (a and P) of each type
(RI, RII, C) of subunit.
One of the main purposes of the present study was to find
out if any specific type ofexpressional change correlated with
tissue growth or regression in in vivo experimental models.
This was done for the sake of the general interest in cor-
relating cAK and growth, and to screen for parameters
relating to cAK subunit expression which might prove useful
to judge the growth potential in biopsies from human
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tumours. Oestrogen-responsive normal and malignant tissue
(uterus and DMBA-induced mammary carcinomas of the rat)
were chosen as model systems. Isozyme specific antibodies
were used to discriminate RI and RII, and Northern blots of
mRNA were used to discriminate the subforms on the level
of mRNA expression.
The experimental models were chosen partly because mam-
mary carcinomas appear particularly interesting regarding
cAK expression. The ratio between the concentrations of
oestrogen receptor and R has appeared useful to predict the
response to endocrine therapy. Both for human mammary
carcinoma (Kvinnsland et al., 1983; Miller et al., 1985; Wat-
son et al., 1987) and DMBA-induced mammary carcinoma in
the rat (Bodwin et al., 1980) this parameter was more reliable
than steroid receptor levels alone. Recently, tumour relapse
rate and patient survival was found to correlate with the
concentration of R subunits in tissue homogenates from
human primary mammary tumours (Miller et al., 1990). One
purpose of the present study was to see if this simple
parameter (concentration of R) was related to the growth
response to oestrogen in experimental systems. This could
provide a basis for understanding the apparent usefulness of
this parameter. Another major purpose was to screen the
more sophisticated parameters ofcAK expression for correla-
tion with growth state.
Materials and methods
Materials
[5':8-3H]cAMP (45 Ci/mmol), [7y-32P]ATP (3000 Ci/mmol), [a-
32P]dCTP (3000 Ci/mmol), [methyl_3H]thymidine (40-60 Ci/
mmol), DNA multiprime labelling kit, and Hybond-N nylon
membranes were from The Radiochemical Centre, Amer-
sham, UK. Phosphate acceptor heptapeptide ('kemptide',
Leu-Arg-Arg-Ala-Ser-Leu-Gly), aprotinin and soybean tryp-
sin inhibitor were from Sigma, St. Louis, MO, USA. Anti-
pain, leupeptin, chymostatin and pepstatin were from the
Peptide Institute, 4-1-2-Ina, Minoshi, Osaka 562, Japan. Pro-
tein A-Sepharose (C14B) was from Pharmacia, Uppsala,
Sweden. Triton X-100 and the gamma globulin protein stan-
dard were from Bio-Rad Laboratories, Richmond, CA,
U.S.A. Water-saturated phenol (puriss.) was from Fluka,
Buchs, Switzerland, and was not redistilled before use. Am-
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monium sulfate (analytical grade) and most other chemicals
were from Merck, Darmstadt, FRG. RIa-cDNA, RID-
cDNA, RIIa-cDNA, Ca-cDNA and CP-cDNA were gifts
from Drs G.S. McKnight, J. Scott and E.G. Krebs, Univer-
sity of Washington, Seattle, WA, USA. RIIP-cDNA was
from Dr T. Jahnsen, University of Oslo, Norway, 17p-
estradiol (Sigma) was dissolved in ethanol and diluted 10-fold
in phosphate-buffered saline just before injection.
Animals
Sprague-Dawley female rats carrying DMBA-induced mam-
mary carcinomas were obtained from the National Cancer
Institute Laboratory at Bethesda, USA (Huggins et al., 1961;
Escrich, 1987); 54 female rats weighing 120-200 g were used
in the experiments. Thirty three rats had a varying number of
primary mammary carcinomas along the mammary lines, 76
tumours in all.
Experimental set-up
Forty-four rats were ovariectomised 10 days prior to treat-
ment with oestrogen, and ten animals were sham-operated.
Tumour-diameters were determined with callipers at the time
of ovariectomy or sham-operation and before animal
sacrifice. Of the 44 ovariectomised animals, 27 were given
daily s.c. injections of 200jig 17p-estradiol and killed after
1-10 days. The oestrogen injections were given at 9 a.m. A
pharmacological rather than a physiological replacement
dose of oestrogen was chosen to induce a transient burst of
DNA-synthesis only. One hour before killing, each animal
received 250 yCi [methyl-3H]thymidine and 5 mg of the
protease-inhibitor leupeptin intraperitoneally. Whole tumours
and uteri were removed from the animal under ether-
anaesthesia and freeze-clamped. The frozen tissue was
pulverised in liquid nitrogen and stored in liquid nitrogen
until further processing. From some tumours biopsies were
taken before ovariectomy adding samples to the non-
castrated control group or before oestrogen treatment adding
samples to the castrated group (Table I).
Two animals (not ovariectomised, and not included in the
main group of 44 animals belonging to the main experiment
detailed above), each with 3 mammary carcinomas, were
treated with N6-monobutyryl cAMP by subcutaneous injec-
tions of 3,33 mg every 8th hour for 1 or 2 days. This was
done to see if there was any alterations in tumour cAK
expression in response to high doses of cAMP.
Preparation ofcytosol andparticulatefractions oftissue
Tissue powder (70-170 mg) was homogenised (2 x 10 s) with
a Polytron PT 10/35 emulsifier (at a setting of 4) in 2 ml of
ice cold homogenisation buffer: 50 mM Hepes-NaOH, pH
7.2, containing 5 mM EDTA, 3 mM EGTA, 120 mM NaCl,
1 mM DTE and the protease inhibitors: aprotinin (0.05
mgml-'), soy bean trypsin inhibitor (1 mgml'), leupeptin
(100 JLM), pepstatin (20jLM), chymostatin (10jaM), antipain
(10 laM), and benzamidine (10 mM). The homogenate was
split in two or three. One portion was kept for measurement
of total DNA. The second portion was made 1% in Triton
X-100, incubated for 1 h at 0°C and used for determination
of RI, RII, and C in the unfractionated homogenate. A third
portion was centrifuged (120 000 x gay.) for 10 min at 4°C in
the A-95 rotor of a Beckman Airfuge to separate the cytosol
(supernatant) and particulate fraction (sediment). The sedi-
ment was washed (resuspended and recentrifuged as above)
in 2 ml ofice cold homogenisation buffer followed by incuba-
tion for 1 h at 0°C in 1 ml of homogenisation buffer contain-
ing 1% of Triton X-100. The fractions (crude and Triton-
treated homogenate, cytosol and Triton-treated particulate)
were stored in small aliquots in liquid nitrogen.
Determination ofprotein kinase subunits
This was done as previously described (Ekanger & D0ske-
land, 1987). The determination of RI or RII was based on
measurement of the binding capacity for [3H]cAMP and
separation using specific, immobilised antibodies. The am-
ount of C subunit was determined by assaying its phospho-
transferase activity at 30°C in 50 mM potassium phosphate,
15 mM HEPES, 10 mM magnesium acetate, 70 tLM 'kemptide',
0.1 mM [32P]ATP (2 ltCi/mmol), 0.5 mM EGTA, 0.1 mM
EDTA, 1 mM DTE, 0.2 mM 3-isobutyl-1-methyl-xanthine,
and 10 iM cAMP (when present). The kinase activity was
stimulated 10-fold by cAMP, and was inhibited 95-99% by
a specific protein kinase inhibitor (Houge et al., 1990b). It
was ensured that the kinase activity was linear with respect to
the concentration of extract and the time of incubation. At
the highest dilutions of extract it was important to ensure as
low blank values as possible to measure the kinase activity
with confidence. It was found that the j[32P]ATP supplied
produced very low blanks only when fresh (the first 1-2
weeks after production). The kinase activity is expressed as
units, i.e. nmol phosphate incorporated into 'kemptide' per
minute under the above conditions. For unknown reasons
the apparent kinase activity varied within a range of ± 15%
between assays. In order to 'normalise' the data obtained at
different occasions purified type I cAMP-dependent protein
kinase from rat skeletal muscle was assayed for kinase
activity and cAMP binding capacity in parallel with the
samples from tumours and uterus. For the purified enzyme
the ratio between binding activity (pmol) and kinase activity
(U) was 1.25.
Determination ofProtein, DNA and[methyl-3H]-thymidine
incorporated into DNA
Protein was determined by the Bio-Rad version of the assay
of Bradford (Bradford, 1976), using bovine gamma globulin
as the standard. It may be noted that the protein values
obtained using this protein standard were about 2.5 times
higher than with bovine serum albumin as the standard. The
Table I Statistical evaluation of different cAK parameters in mammary tumours
Control: Two-tailed Wilcoxon
Castration t-test rank sum test
Control Castration ratio P-value P-value
Relative tumour sizea 1.70 (1.38-3.25/n = 23) 0.56 (0.57-2.07/n = 44) 3.04 0.02 0.0001 [3H]-thymidine d.p.m./fLg DNA 21.5 (19.1-28.7/n = 21) 7.7 (5.7-12.8/n = 25) 2.80 0.03 0.0001
RI (pmol/mg protein) 3.27 (2.99-3.99/n = 25) 2.35 (2.20-2.76/n = 35) 1.39 0.0003 0.0008
RII (pmol/mg protein) 1.94 (1.76-2.42/n = 25) 1.47 (1.38-1.74/n = 35) 1.32 0.004 0.013
RI/RII 1.76 (1.64-2.00/n = 25) 1.61 (1.54-1.83/n = 35) 1.12 0.17 0.13
Total R (RI + RII) 5.47 (4.78-6.37/n = 25) 3.85 (3.62-4.46/n = 35) 1.42 0.0001 0.0003 C (units/mg protein) 2.41 (2.20-2.83/n = 25) 2.33 (2.19-2.72/n = 35) 1.03 0.75 0.78
R/C 2.21 (2.06-2.92/n = 25) 1.68 (1.53-2.02/n = 35) 1.39 0.009 0.02
The table shows the geometrical mean of tumour growth parameters (crude size measurements and estimated radioactive thymidine incorporation) and cAMP kinase isozyme levels and ratios in tumours from castrated animals compared to uncastrated controls. The 95%
confidence intervals and number of samples (n) are given in the parentheses. The exact P-values derived from the use of two-tailed Students
t-test or Wilcoxon's rank sum test are given in the two right-hand columns. aTumour size relative to the size measured at the start of the experiment.1024 G. HOUGE et al.
determination of DNA was according to a modification
(Vintermyr & D0skeland, 1987) of the procedure of Patter-
son (Patterson, 1979). Before spectrophotometric determina-
tion of DNA, an aliquot of the sample was removed to
determine the amount of [methyl-3H]-thymidine incorporated
into DNA by liquid scintillation counting.
Isolation oftotal RNA and hybridization with cDNA probes
Total RNA was isolated according to the procedure des-
cribed by Chomczynsky et al. (Chomczynsky & Sacchi,
1987). Mammary carcinoma tissue was homogenised with a
Dounce tissue grinder in 1 ml of 25 mM sodium citrate buffer
pH 7.0 containing 4 M guanidinium thiocyanate, 0.5% sod-
ium lauroylsarcosine (w/v) and 1% 2-mercapto-ethanol (v/v).
Rat uteri were homogenised in 2 ml of the above mentioned
solution with a Polytron PT 10/35 homogeniser for 45 s (at a
setting of 9). Further purification and Northern blotting of
RNA was done as described previously (Houge et al., 1990a).
The RNA nylon membranes were hybridised with 32P-dCTP
labelled probes made by random primed labelling of Rla-,
RIP-, RIoa-, Rllp, Co- and CP-cDNA fragments. Auto-
radiography was performed with preflashed film at - 70°C,
2-20 days exposure. The hybridisation signals were mea-
sured using the LKB UltroScan XL Laser Densitometer.
= 1.6
1.2
: 1.5
1.3
X 1.1
17
.> 9
Z a)
~ 3
:,2
._ ._
°CU
-
Days after ovariectomy (ov x)
Results
Expression ofcAMP-kinase subunits in uterine tissue
Ovariectomy led as expected to a decline in uterine DNA
synthesis and protein content (Figure 1, lower two panels). In
order to study in more detail the relation between cAK
expression and oestrogen dependent growth, ten days pos-
tovariectomy rats were treated with high doses of 17p-
estradiol to induce a transient increase in DNA synthesis.
The DNA synthesis peaked 36 h after commencement of
such treatment and approached uncastrated control level 12 h
thereafter (Figure 1). The data are in agreement with the
triggering by estradiol of one wave of coordinated DNA
replication in the uterine epithelium (Figure 1, Figure 2b).
Uterine protein content and weight increased continuously
during the period studied (Figure 1). Stromal oedema was
microscopically evident after 1 day of estradiol treatment
(Figure 2b). These findings established that the treatment
used had the effect on uterus expected from a high dose
estradiol regimen (Lavia et al., 1984; Lee, 1972; Martin et al.,
1973; Stormshak et al., 1976).
The uterine expression of the regulatory subunit of cAK
isozyme I (RI) was sensitive to the endocrine state of the
animal. RI decreased in response to castration, and tran-
siently increased in response to high-dose estradiol treatment.
In contrast, the concentration of the C subunit of cAK was
constant (when expressed relative to uterine protein) during
oestrogen treatment, and RII showed only minor fluctua-
tions. Therefore, the values of the derived parameters RI/Rll
and R/C (Figure 1) decreased after castration and increased
during the first 36 h of estradiol treatment. These parameters
correlated thus positively with the burst of DNA replication.
The increasing amount of tissue oedema in the endometrium
presumably led to accumulation of extracellular serum-de-
rived proteins invalidating the protein determinations as a
measure of intracellular protein. Presumably this was why
the R/protein data did not show the same clear correlation
with DNA synthesis as RI/Rll and R/C (data not shown).
The uterine cAMP-kinase was mainly cytosolic, i.e. only
7% of total RI and 13% of total RII were found in the
particulate fraction in either castrated or oestrogenised uteri
(data not shown). There was therefore no indication of
growth associated translocation of protein kinase subunits
between the soluble and particulate compartments.
The antibodies used to separate RI and RII do not dis-
criminate between the a and 13 subtypes of RI and RII. In
order to know if estradiol treatment specifically affected the
Figure 1 Growth-related changes in RI/Rll (top figure) and R/C
(second figure from the top) in the rat uteri. Uterine DNA
synthesis was measured as 3H-thymidine incorporation/mg DNA
(second figure from bottom), and uterine protein synthesis as mg
protein/uterus (bottom figure). The abscissa indicates the tem-
poral relation between the samples, i.e. before ovariectomy, 10
days after ovariectomy and days of estradiol treatment. The
second figure gives the relation between R subunit and C subunit
in arbitrary units (pmol cAMP binding capacity/kinase units).
Rat muscle cAKI holoenzyme assayed under similar conditions
had a R/C ratio of 1.25. The symbols represent geometrical
means of 3 or 4 uteri (average 3.25), and the bars show the
standard error of the mean.
expression of a particular subtype of RI or RII, the amounts
of mRNA for both the a- and P-subtypes of RI and RII were
determined on Northern blots (Figure 3). The rat uterus was
found to contain mRNA for both subtypes of RI and RII.
The mRNA coding for the a-subtype of RI was at least ten
times more abundant than the RIP-mRNA. The difference in
mRNA level for the a and P RII subtype was less, but still in
favour of the a-subtype. There were no major differences in
relative expression of subtypes upon estradiol treatment with
the exception of the RII3-mRNA level which was transiently
increased 12 h after oestrogen replacement (Figure 3). It is
not known if this increase in RIIP-mRNA was accompanied
by an increase in RIIP protein because rat-RIIP specific
antibodies were not available. Judged by the RIIa- and RIIP-
mRNA signal intensities and the exposure times (Figure 3), it
is likely that RIIa is the dominating RII subtype in the
uterus. The finding that no increase in RII protein level was
found 12 or 24 h after oestrogen-stimulation gives this as-
sumption further credit. The presence of RI,B-mRNA in
uterus is of interest, since this particular subtype has been
considered specific for brain and testis (Clegg et al., 1988;
Massa et al., 1990) (Figure 3). No CP-mRNA was detected
on the same Northern blots.
cAMP-kinase isozyme expression in DMBA-induced rat
mammary tumours
The findings for rat uterus (preceding paragraph) showed a
correlation between growth changes and expression of partic-
ular protein kinase subunits. It was of interest to find if
similar correlation existed in other hormone-dependent sys-
tems, like the oestrogen-dependent DMBA-induced mam-cAMP-KINASE EXPRESSION IN MAMMARY CARCINOMAS AND UTERI 1025
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Figure 2 Autoradiographic and histological appearance of rat uteri (left pictures) and mammary tumours (right pictures). a and d: 10 days after ovariectomy. b and e: 24 h after an injection of 200fig estradiol subcutaneously. c and f: after 4 days of daily s.c. 200jg estradiol injections. The arrows indicate nuclei with DNA synthesis.
mary carcinoma. For this, biopsies from subcutaneously
growing tumours were removed before castration and ten
days after castration and analysed for size, DNA synthesis
and expression of protein kinase subunits (Table I). One
hour before tumour biopsies were taken, the rats were intra-
peritoneally injected with 5 mg of the protease inhibitor
leupeptin. This was to protect the protein kinase subunits
against proteolytic breakdown during the process of tumour
removal, tissue freezing and homogenisation. Histological
analysis of several tumours showed typical adenocarcinomas
with sparse connective tissue (Figure 2d-f; see also Cohen &
Chan, 1975). Autoradiography confirmed that DNA syn-
thesis was chiefly in the tumour cells and that the DNA
synthetic activity in these cells decreased after castration.
Table I shows that ten days after ovariectomy the DNA
replicative activity and the average tumour size had de-
creased about three fold. Both R/protein and R/C had
decreased significantly. The decrease of the concentration of
total R was due to a decrease of both RI and RII. The level
of C did not change significantly. There was no evidence of
altered distribution of protein kinase subunits between parti-
culate and soluble fractions (data not shown).
Northern blot analysis of total RNA revealed a low level
of RIIP-mRNA expression and higher levels of mRNAs for
the a-subforms of RI, RII and C (Figure 3). mRNAs for RIP
and Cp were not detected on the same membranes. There
was no gross difference in cAMP-kinase mRNA levels be-
tween tumours from untreated and ovariectomised animals
(Figure 3).
In order to test further for a link between DNA synthesis
and kinase subunit expression, some animals were subjected
to the high-dose oestrogen treatment described above. Such
treatment of castrated animals gave a transient increase in
DNA synthesis but no detectable increase in tumour size
(Figure 4; see also Meites, 1972; Escrich, 1987). As shown in
Figure 4 the pattern of expressional change of cAMP-kinase
subunits was similar to that observed in the oestrogen treated
rat uterus (Figure 1). It thus seems that the temporary in-
crease in the parameters RI/RII and R/C are positively corre-
lated with hyperplasia in either of the two oestrogen dependent
experimental systems studied. The uterus differed from the
mammary tumours with respect to the trophic effect of long-
term high-dose estradiol treatment. Whereas protein, weight
and to a lesser extent DNA per uterus steadily increased
during the first ten days of treatment, the same parameters
decreased in the case of the tumours. The tumour involution
was presumably due to accelerated (apoptotic) death of the
carcinoma cells, since the proportion between tumour cells
and stroma decreased although tumour cells undergoing
active DNA-synthesis were observed after 4 days of oest-
41026 G. HOUGE et al.
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Figure 3 Northern blot showing the mRNA signals for the
different subtypes of cAMP-dependent protein kinase. Typical
examples of the expression found in a, mammary tumours from
control and castrated animals and b, uteri from control, castrated
and oestrogen-treated animals are shown. The approximate size
of the mRNA bands are indicated on the left and the cDNA
probe used during the hybridisation is indicated on the right. The
exposure times varied, being 2 days for uterine RIa and RIIac, 4
days for mammary RI, RIIa and Cot, 7 days for uterine RIIp
and Co and 20 days for uterine RIP. All membranes were washed
with high stringency (0.1 x SSPE/0.1% SDS at 50'C).
rogen treatment (Figure 2f). None of the tumours showed
necrotic areas. The only apparent difference between the cAK
expression parameters in long-term treated uteri and car-
cinomas was a slower return of the estradiol-induced increase
of RI/Rll ratio in the former (Figures 1,4).
As explained in the Materials and methods section six
biopsies of mammary tumours were taken from animals
treated with N6-monobutyryl cAMP. This was done to see if
cAMP could induce the same increase in R/C ratio as
observed in other systems (Schwoch, 1987; Houge et al.,
1990a). A cAMP-induced increase in R/C was found due to
an increase of RII and to a lesser extent of RI (Table II). No
change was found in the level of C or the DNA-synthetic
activity.
Discussion
The biological significance of an increased cAMP level can
only be fully understood if the state of the cAMP-effector
system, the cAMP-dependent protein kinase, is known.
Usually, the proportion between R and C is close to 1:1 in
normal tissue (Hofmann et al., 1977). However, hepatocytes
0.
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Figure 4 Growth related changes in total R (top figure), RI/RhI
(second figure from the top) and R/C (middle figure) in a subset
of DMBA mammary tumours from animals that were exposed to
the same high-dose oestrogen regimen as in Figure 1. The values
on the ordinate and abscissa are as in Figure 1. The symbols
represent geometrical means of 2 to 13 tumours (average 5.4). As
in Figure 1, s.e.m. values are shown by bars.
Table II [3H]-thymidine incorporation and cAMP-kinase subunit
expression in tumours treated with N6-MB-cAMP
Control 36 h N6-MB-cAMP
(n =8) treatment (n = 6)
[3H]-thymidine d.p.m./pg DNA 22.5 ± 3.2 26.9 ± 3.9
RI (pmol/mg protein) 3.20 ± 0.26 3.80 ± 0.65
RII (pmol/mg protein) 1.69 ± 0.32 2.56 ± 0.37
RI/Rll 1.84 0.15 1.60 0.23
Total R (RI + RII) 5.08 ± 0.40 6.43 ± 0.98
C (units/mg protein) 2.27 ± 0.26 2.19 ± 0.25
R/C 2.49 0.25 2.95 0.52
The table shows the geometrical means of tumour cAMP-kinase
parametes in the experiment where non-castrated rats were treated
with N6-monobutyryl-cAMP. Standard error of the mean and the
number of tumours (n) is indicated.
undergoing compensatory hyperplasia after partial hepatec-
tomy (Ekanger et al., 1989) and parotid epithelial cells
induced to proliferate by isoproterenol (Schwoch, 1987) in-
crease their R/C ratio before DNA replication. In the present
study, an increased R/G-ratio was found to correlate posi-
tively with proliferation of both rat uterine cells and rat
mammary carcinoma cells (Figures 1,4; Table I). An in-
creased R/C ratio may therefore accompany increased
growth of epithelial cells (both normal and malignant) in
vivo.
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An increased R/C-ratio results in a higher threshold for
kinase activation, i.e. the amount of cAMP required for
liberation of a certain amount of active C will be elevated.
The equilibrium:
R2C2 + 4(cAMP) = R2(cAMP)4 + 2C
is shifted to the left. In addition, the extra R will serve as a
sink for cAMP (for a theoretical discussion of the effect of an
altered R/C ratio, see Houge et al., 1990a). Even a modest
change in free C may have dramatic biological effects assum-
ing that cAK participates in a finely tuned system of phos-
phorylation and dephosphorylation. This means that cells
with an increased R/C ratio will show partial resistance to
cAMP. A good illustration of this point has recently arrived
from the experiments done to find the tissue specific extin-
guisher (TSE1) in liver cells (Boshart et al., 1991; Jones et al.,
1991). After 10 years of research, the TSE1 turned out to be
RIa. When liver cell Rla level is reduced at the time ofbirth,
some genes with cAMP responsive elements in their pro-
moters are turned on. If hepatoma cells are fused with cells
more strongly expressing Rla (e.g. fibroblasts), these tissue
specific liver genes are turned off again.
The consequence of the partial cAMP resistance resulting
from increased R/C ratio depends on the effect of elevated
cAMP on cell growth. This is still imperfectly known and to
some extent controversial (Boynton & Whitfield, 1983; Got-
tesman & Fleischmann, 1986). Normal hepatocytes have a
biphasic response, i.e. stimulation by moderate cAMP and
inhibition by strongly elevated cAMP (Br0nstad et al., 1983;
Vintermyr et al., 1989; Thoresen et al., 1990). In the regen-
erating rat liver we have proposed that the prereplicative
cAMP surge (MacManus et al., 1972) acts to inhibit the
G1/S transition, and that the block in late GI is overcome
partly because of the increased R/C ratio occurring prerep-
licatively (Ekanger et al., 1989). A similar mechanism may
operate in the case of the isoproterenol-stimulated prolifera-
tion ofparotid gland epithelium (Schwoch, 1987). In the case
of human mammary carcinoma cell lines the findings are
controversial (Handschin & Eppenberger, 1979; Eppenberger
et al., 1980; Prasad, 1981; Handschin et al., 1983; Israeli et
al., 1985). Using an oestrogen responsive MCF-7 cell line, we
first failed to obtain effects on DNA replication of cAMP
elevating agents and cAMP analogues. However, when the
phosphodiesterase activity of the cells was blocked a clear
inhibition of DNA replication by cAMP could be demon-
strated. Furthermore, microinjection of the C subunit of
cAMP-dependent protein kinase led to inhibition of DNA
replication (0. Vintermyr, A. Aakvaag & S.O. D0skeland,
unpublished observations). The current evidence suggest to
us that the growth associated increase of R/C ratio observed
in liver (Ekanger et al., 1989), parotid (Schwoch, 1987), and
uterus and mammary carcinoma (the present study) serves to
protect cells against negative modulation of DNA replication
by cAMP. The importance ofdownregulation ofcAK for cell
cycle progression is further supported by a recent study using
microinjection of an inhibitor of cAK into fibroblasts (Lamb
et al., 1991).
The mechanism ofthe increased R/Cratio may in principle
be an increase ofeither RI or RII or a decrease of C subunit.
In the case of the oestrogen-stimulated uterus and DMBA-
induced mammary carcinomas the increase was mainly due
to increased expression of RI (Figures 1,4). In mammary
carcinomas from animals treated with cAMP-analogue RII
and to a lesser extent RI showed increased expression (Table
II). This difference suggests that the oestrogen-dependent
overexpression of RI was not secondary to increased cAMP.
In growth-stimulated DMBA-induced mammary tumours,
both the RI and RII levels were higher than in oestrogen- deprived tumours (Table I), a situation reminiscent of the
findings in the prereplicative regenerating rat liver, where
both RI and RII rose to increase the R/Cratio (Ekanger et
al., 1989). It is noteworthy that a decrease of C did not
contribute to the growth-associated increased R/C ratio in
the DMBA-tumours (Table I). A slight decrease of C cont-
ributed to the increased R/C-ratio in prereplicative
regenerating rat liver (Ekanger et al., 1989), whereas
decreased C was the main contributor to the increased R/C-
ratio in isoproterenol-stimulated rat parotid cells (Schwoch,
1987), cAMP-stimulated hepatocytes in primary culture
(Houge et al., 1990a) and porcine kidney cells (Hemmings,
1986), e.g. in cells stimulated by cAMP. However, a decrease
in C due to strong cAMP-stimulation is not compulsory. In
this study, no decrease in C was found after treating uncast-
rated rats with cAMP-analogue (Table II). Similar findings
have been done in various cell culture systems (Prasad, 1981;
Lohmann & Walter, 1984; Gross et al., 1990; Landmark et
al., 1991; Lanotte et al., 1991).
A parameter which has been positively associated with
growth in studies dating back more than a decade (D0ske-
land et al., 1975; Russel, 1978; Cho-Chung, 1990) is the
RI/RII ratio. In the present study the oestrogen-induced
burst of DNA-synthesis was associated with increased RI/RII
ratio (Figures 1,4), but the correlation was too weak to be
statistically significant for the DMBA-tumours (Table I). The
latter finding was somewhat suprising. In human mammary
carcinomas the RI/RII ratio was found to be higher than in
adenomas as judged by DEAE cellulose chromatography
(Eppenberger et al., 1980). It may be noted, as a general
precaution when comparing studies of cAK isozyme expres-
sion, that the use of DEAE-cellulose to separate RI-holoen-
zyme from RII-holoenzyme is more error-prone (Malkinson et
al., 1983) than the use of antibodies (Ekanger & D0skeland,
1987). In non-steroid sensitive systems a positive correlation
between RI and growth is supported by the following findings:
cAMP analogue combinations preferentially activating type I
isozyme of cAMP kinase were more efficient stimulators of
thyrocyte DNA replication than type II directed combina-
tions (Van Sande et al., 1989); prolonged treatment with a
thyroid stimulating hormone led to a parallel decrease of RI
and the ability to respond to cAMP with increased prolifera-
tion (Breton et al., 1989) and HL-60 leukaemia cells trans-
fected with antisense oligodeoxynucleotide directed against
RIa showed decreased growth (Tortora et al., 1991). The
uterine RI/RII ratio stayed elevated after the initial burst of
oestrogen-induced DNA replication, i.e. when the uterus
grew by hypertrophy rather than hyperplasia (Figure 1).
Such a hypertrophy-associated increase of RI/RII ratio has
also been found in the heart (Russel, 1978) and liver
(Ekanger et al., 1988). A possible explanation, supported by
the findings in rat liver (Ekanger et al., 1988), is that hyper-
trophying cells preferentially increase RI to keep their cyto-
plasmic concentration of R on a constant level. A preferential
increase of RI was also found in transfected fibroblasts
overexpressing the C subunit (Uhler & McKnight, 1987). It
appears thus that although the present study contributes
additional examples of association between increased RI/Rll
ratio and increased DNA synthesis and cell hypertrophy,
such a correlation is not obligatory (e.g. Wittmaack, et al.,
1983).
This study did not provide indication of differential cAK
subtype function in relation to growth, based on mRNA
studies (Figure 3). If the mRNA level of Ca is used as a
reference, the only clear evidence of differential mRNA ex-
pression found was a three fold increase in uterine RIIP-
mRNA 12 h after onset of high-dose oestrogen stimulation
(Figure 3). High inducibility of RIIP-mRNA has also been
found in Friends erythroleukaemia cells, where RIIP-mRNA
was stabilised post-transcriptionally after activation of cAK
(Gross et al., 1990). It is not known if the increase in
R1IP-mRNA can be linked to increased cAMP level in our
case. It is noteworthy that RIP-mRNA was detected on
conventional Northern blots in the uterus. RIP-mRNA has
previously only been found in the brain and germ cells (Clegg
et al., 1988; Massa et al., 1990), and the significance of its
expression in uterus is not known. However, recent
experiments with holoenzymes reconstituted with Rhaand
RIP, have shown the latter to be more sensitive to activation
by cAMP (Cadd et al., 1990). An overexpression of RI,B
relative to RIh would therefore be expected to lower the
threshold of the kinase towards activation by cAMP.1028 G. HOUGE et al.
In the clinical setting the oestrogen receptor/R was a better
parameter than oestrogen receptor/protein in predicting a
tumour's response to endocrine therapy (Kvinnsland et al.,
1983). In addition the parameter R/protein (or total cAMP
binding capacity) has been shown to be an independent
prognostic factor for patients with early breast cancer (Miller
et al., 1990). In the present experimental study the ratios
R/protein and R/C were tightly associated because the C
subunit level was nearly constant (Figure 4; Table I). As
reviewed above there is an increasing number of in vivo
examples of increased R/C ratio in cells in transition from a
resting state to a proliferating state (Figures 1,4; Table I).
The increased R/C will protect the cells from negative regula-
tion of proliferation by cAMP (D0skeland et al., 1991).
Possibly, mammary tumours with increased R expression
have increased resistance to endocrine therapy.
The parameter R/protein depends on the determination of
protein in an extract of tumour which may contain extracel-
lular proteins and debris of protein nature from necrotic
cells. This may explain why the R/protein values differ in
different parts of the same tumour (Miller et al., 1985). Since
the amount of C subunit reflects the content of a cell protein,
and the ratio between R and C subunits has biological
significance, the R/C ratio may be a better parameter than
R/protein for clinical purposes.
It was noted that ageing of tissue extracts led to rapid loss
of immunoreactive RII, whereas total R (determined by
direct cAMP binding capacity) was much more stable. This
was presumably because tissue proteases clipped the cAMP
binding domain from the aminoterminal domain containing
the epitopes recognised by the antibodies. In the clinical
setting, proteolysis can be a major problem for the accurate
determination of RI and especially RII. In the present study
several precautions were taken to avoid the loss of
immunoreactive R: The tissue was freeze-clamped at the
temperature of liquid nitrogen, grinded in liquid nitrogen and
kept in that medium until homogenisation. Special care was
taken to inhibit proteases during the homogenisation and
immunoprecipitation, involving the use of an extensive pro-
tease-inhibitor cocktail (see methods) and doing all the work
on ice or in the cold-room. As an extra precaution the rats in
this study were intraperitoneally injected with leupeptin 1 h
before tumour removal.
In summary, the direct determination of R and C is sim-
pler and 'safer' than the separate measurement of RI and
RII. RI, RII or RI/RII shows no better correlation with
growth than R or R/C (Table I). The R level should be
referred to the C level to calculate the biologically significant
R/C ratio and to have a reference for R that is methodo-
logically less problematic than protein measurements.
The technical assistance of Erna Finsas was highly appreciated. This
work was supported by the Norwegian Cancer Society (DNK) and
the F. Meltzer Foundation.
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